PRQR PE Ratio & Valuation,Is PRQR Overvalued

PRQR Relative Valuation

PRQR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRQR is overvalued; if below, it's undervalued.

Historical Valuation

ProQR Therapeutics NV (PRQR) is now in the Fair zone, suggesting that its current forward PS ratio of 11.43 is considered Fairly compared with the five-year average of -5.15. The fair price of ProQR Therapeutics NV (PRQR) is between 1.85 to 2.45 according to relative valuation methord.

Relative Value

Fair Zone

1.85-2.45

Current Price：2.31

Fair

-4.30

0.00

EV/EBITDA

ProQR Therapeutics NV. (PRQR) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.79. The thresholds are as follows: Strongly Undervalued below -6.36, Undervalued between -6.36 and -4.08, Fairly Valued between 0.49 and -4.08, Overvalued between 0.49 and 2.78, and Strongly Overvalued above 2.78. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-2.36

EV/EBIT

ProQR Therapeutics NV. (PRQR) has a current EV/EBIT of -2.36. The 5-year average EV/EBIT is -2.77. The thresholds are as follows: Strongly Undervalued below -8.89, Undervalued between -8.89 and -5.83, Fairly Valued between 0.28 and -5.83, Overvalued between 0.28 and 3.34, and Strongly Overvalued above 3.34. The current Forward EV/EBIT of -2.36 falls within the Historic Trend Line -Fairly Valued range.

11.43

ProQR Therapeutics NV. (PRQR) has a current PS of 11.43. The 5-year average PS is 77.09. The thresholds are as follows: Strongly Undervalued below -258.36, Undervalued between -258.36 and -90.64, Fairly Valued between 244.82 and -90.64, Overvalued between 244.82 and 412.55, and Strongly Overvalued above 412.55. The current Forward PS of 11.43 falls within the Historic Trend Line -Fairly Valued range.

-3.90

P/OCF

ProQR Therapeutics NV. (PRQR) has a current P/OCF of -3.90. The 5-year average P/OCF is -4.60. The thresholds are as follows: Strongly Undervalued below -13.28, Undervalued between -13.28 and -8.94, Fairly Valued between -0.26 and -8.94, Overvalued between -0.26 and 4.08, and Strongly Overvalued above 4.08. The current Forward P/OCF of -3.90 falls within the Historic Trend Line -Fairly Valued range.

-3.47

P/FCF

ProQR Therapeutics NV. (PRQR) has a current P/FCF of -3.47. The 5-year average P/FCF is -7.04. The thresholds are as follows: Strongly Undervalued below -17.52, Undervalued between -17.52 and -12.28, Fairly Valued between -1.80 and -12.28, Overvalued between -1.80 and 3.43, and Strongly Overvalued above 3.43. The current Forward P/FCF of -3.47 falls within the Historic Trend Line -Fairly Valued range.

ProQR Therapeutics NV (PRQR) has a current Price-to-Book (P/B) ratio of 3.67. Compared to its 3-year average P/B ratio of 3.86 , the current P/B ratio is approximately -4.87% higher. Relative to its 5-year average P/B ratio of 3.33, the current P/B ratio is about 10.18% higher. ProQR Therapeutics NV (PRQR) has a Forward Free Cash Flow (FCF) yield of approximately -23.63%. Compared to its 3-year average FCF yield of -14.33%, the current FCF yield is approximately 64.88% lower. Relative to its 5-year average FCF yield of -22.95% , the current FCF yield is about 2.98% lower.

3.67

P/B

Median3y

3.86

Median5y

3.33

-23.63

FCF Yield

Median3y

-14.33

Median5y

-22.95

Competitors Valuation Multiple

The average P/S ratio for PRQR's competitors is 12.53, providing a benchmark for relative valuation. ProQR Therapeutics NV Corp (PRQR) exhibits a P/S ratio of 11.43, which is -8.76% above the industry average. Given its robust revenue growth of -26.78%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of PRQR decreased by 12.08% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -203.67 to -377.56.

The secondary factor is the Revenue Growth, contributed -26.78%to the performance.

Overall, the performance of PRQR in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-26.78%

3.98M → 2.92M

Revenue Growth

85.38%

-203.67 → -377.56

Margin Expansion

-70.68%

-16.50 → -4.84

P/E Change

-12.08%

2.65 → 2.33

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is ProQR Therapeutics NV (PRQR) currently overvalued or undervalued?

What is ProQR Therapeutics NV (PRQR) fair value?

PRQR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of ProQR Therapeutics NV (PRQR) is between 1.85 to 2.45 according to relative valuation methord.

How does PRQR's valuation metrics compare to the industry average?

What is the current P/B ratio for ProQR Therapeutics NV (PRQR) as of Dec 15 2025?

As of Dec 15 2025, ProQR Therapeutics NV (PRQR) has a P/B ratio of 3.67. This indicates that the market values PRQR at 3.67 times its book value.

What is the current FCF Yield for ProQR Therapeutics NV (PRQR) as of Dec 15 2025?

As of Dec 15 2025, ProQR Therapeutics NV (PRQR) has a FCF Yield of -23.63%. This means that for every dollar of ProQR Therapeutics NV’s market capitalization, the company generates -23.63 cents in free cash flow.

What is the current Forward P/E ratio for ProQR Therapeutics NV (PRQR) as of Dec 15 2025?

As of Dec 15 2025, ProQR Therapeutics NV (PRQR) has a Forward P/E ratio of -4.30. This means the market is willing to pay $-4.30 for every dollar of ProQR Therapeutics NV’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for ProQR Therapeutics NV (PRQR) as of Dec 15 2025?

As of Dec 15 2025, ProQR Therapeutics NV (PRQR) has a Forward P/S ratio of 11.43. This means the market is valuing PRQR at $11.43 for every dollar of expected revenue over the next 12 months.

PRQR Valuation